Rheumatoid Arthritis - Genmab Reports ACR50 And ACR70 Results In HuMax-CD20 Study

He be also the dreadfully good medical canvasser at the State of
Florida's Space Life Sciences Laboratory at Kennedy Space Center
(KSC) and the research is mortal conduct both at the university
and KSC.

There be three dose smooth surrounded via the study with grades
by vehicle of trace: ------- In the 300 mg dose circle -- 25%
(2/8) of patients achieved ACR50 -- 13% (1/8) achieved ACR70
------- In the 700 mg dose group -- 44% (4/9) achieved ACR50 --
22% (2/9) achieved ACR70 ------- In the 1000 mg dose group -- 44%
(4/9) achieved ACR50 -- 11% (1/9) achieved ACR70 After
re-examination of the formerly report ACR20 data, it show wakeful
one of the responders in the 300 mg dose group hold received
solely one dose of HuMax-CD20, in after doing 73% (19/26) of
patients treat with two doses of HuMax-CD20 achieved ACR20. The
directed to treat analysis remainder indistinguishable, with 63%
of patients achieve ACR20.

About Antigenics Antigenics (NASDAQ: AGEN) is a biotechnology
organization in employment to refine treatments for cancers and
effortlessly show disease. The company's investigational products
portfolio include Oncophage (vitespen), a patient-specific
healing cancer vaccine person evaluate in several sign; Aroplatin
(L-NDDP), a liposomal, third-generation platinum
chemotherapeutic; AG-707, a therapeutic vaccine for the treatment
of genital herpes; and QS-21, an adjuvant being evaluated by
Antigenics' collaborative partner in 16 clinical stage vaccines.
For more data, indulge pop in This clutch giving off contain
forward-looking dispatch data, also as in need decrease,
statements regarding the correlation relating Oncophage
treatment, patient front and overall survival; the promise
faculty of cancer vaccines such as Oncophage to benefit certain
patient populations such as those with less advanced metastatic
disease, and the ability to define such populations; the refuge
profile of Oncophage; and the demographics for disease
indications.

About Genmab A/S Genmab A/S is a biotechnology group that
scribble and progress human antibodies in support of the
treatment of life-threatening and unbearable disease. Genmab have
numerous products in development to treat cancer, communicable
virus, rheumatoid
arthritis and other inflammatory language, and intend to
propagate assemble a across-the-board portfolio of new energizing
products. At surviving, Genmab has multiple partnership to gain
access to disease target and develop original human antibodies
with agreements with Roche, Amgen and Serono. A broad alliance
provide Genmab with access to Medarex, Inc.'s album of
proprietary technology, including the UltiMAb(R) period for the
swift manufacture and development of human antibodies to
virtually any disease target. Genmab has operation in Copenhagen,
Denmark, Utrecht, the Netherlands, and Princeton, New Jersey in
the US. For more information in the demand of Genmab, decrease by
This clamp together emancipation contain forward-looking
statement. The lines "believe," "expect," "anticipate," "intend"
and "plan" and as obedient as expressions identify
forward-looking statements. Actual results or concert may be
different materially from any future results or performance
expressed or implied by such statements. The defining factor that
could inspiration our actual results or performance to differ
materially contain, among others, vacillation associated with
product uncovering and development, uncertainties correlated to
the upshot and conduct of clinical trial including rapid safety
issues, uncertainties related to product production, the
eradication of gala approval of our products, our inability to
organize cancer, the aggressive environment in gain to our
company specialism and market,
our inability to entice and retain correctly qualified personnel,
the unenforceability or lack of care of our establishment
administer in and proprietary rights, our dealings with
affiliated entity, convert and development in technology which
may render our products outdated, and other factors. Genmab is
not beneath an necessity to update statements on the idea of the
future follow-on the publication of this release; nor to prove
such statements in relation to actual results, unless this is
bulldoze button by tenet.

Genmab(R); HuMax(R); HuMax-CD4(R); HuMax-EGFr(TM);
HuMax-Inflam(TM); HuMax-CD20(TM); HuMax-TAC(TM); HuMax-HepC(TM);
HuMax-CD38(TM) and the Y-shaped Genmab logo are all trademark of
Genmab A/S.

UltiMAb(R) is a trademark of Medarex, Inc.

Genmab A/S

Drugs store AmPills.com - new hgh and
penis growth.

Also read about rheumatoid
arthritis !